Références
1. Penner IK, Raselli C, Stöcklin M, Opwis K, Kappos L, Calabrese P. The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler. 2009 Dec;15(12):1509-17. doi: 10.1177/1352458509348519. Epub 2009 Dec 7. PMID: 19995840.
2. Doneh B. Epworth Sleepiness Scale. Occup Med (Lond). 2015 Aug;65(6):508. doi: 10.1093/occmed/kqv042. PMID: 26240130.
3. Jason LA, Sunnquist M. The Development of the DePaul Symptom Questionnaire: Original, Expanded, Brief, and Pediatric Versions. Front Pediatr. 2018 Nov 6;6:330. doi: 10.3389/fped.2018.00330. PMID: 30460215; PMCID: PMC6232226.
4. Newton JL, Okonkwo O, Sutcliffe K, Seth A, Shin J, Jones DE. Symptoms of autonomic dysfunction in chronic fatigue syndrome. QJM. 2007 Aug;100(8):519-26. doi: 10.1093/qjmed/hcm057. Epub 2007 Jul 7. PMID: 17617647.
5. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum in: J Am Geriatr Soc. 2019 Sep ;67(9):1991. PMID: 15817019.
6. Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):721-733. doi: 10.1177/1352458517690821. Epub 2017 Feb 16. PMID : 28206827 ; PMCID : PMC5405816.
7. Della Vedova L, Hashemi P, Kleinschmidt A, Meynard A, Arsever S. Stratégies de médecine de premier recours. Céphalées. 2022 https://www.hug.ch/sites/interhug/files/2022-10/strategie_cephalees_06.10.2022.pdf.
8. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307. doi: 10.1016/s1389-9457(00)00065-4. PMID: 11438246.
9. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x. PMID: 6880820.
10. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep ;16(9):606-13. PubMed PMID: 11556941; PubMed Central PMCID: PMC1495268.
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382. PMID: 444788.
12. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992 Sep ;31(3):301-6. doi: 10.1111/j.2044-8260.1992.tb00997.x. Erratum in: Br J Clin Psychol. 2020 Jun;59(2):276. PMID: 1393159.
13. Spallone V, Morganti R, D’Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012 May ;29(5):578-85. doi: 10.1111/j.1464-5491.2011.03500.x. PMID: 22023377.
14. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988 Mar;93(3):580-6. doi: 10.1378/chest.93.3.580. PMID: 3342669.
15. van Dixhoorn J, Duivenvoorden HJ. Efficacy of Nijmegen Questionnaire in recognition of the hyperventilation syndrome. J Psychosom Res. 1985 ;29(2):199-206. doi: 10.1016/0022-3999(85)90042-x. PMID: 4009520.
16. Funke-Chambour M, Bridevaux PO, Clarenbach CF, Soccal PM, Nicod LP, von Garnier C ; Swiss COVID Lung Study Group and the Swiss Society of Pulmonology. Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID. Respiration. 2021 ;100(8):826-841. doi: 10.1159/000517255. Epub 2021 Jun 4. PMID: 34091456; PMCID: PMC8339046.
17. Guler SA, Ebner L, Aubry-Beigelman C, Bridevaux PO, Brutsche M, Clarenbach C, Garzoni C, Geiser TK, Lenoir A, Mancinetti M, Naccini B, Ott SR, Piquilloud L, Prella M, Que YA, Soccal PM, von Garnier C, Funke-Chambour M. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021 Apr 29;57(4):2003690. doi: 10.1183/13993003.03690-2020. PMID: 33419891; PMCID: PMC8082329.
18. Hôpitaux Universitaires de Genève. Post-COVID-Prise en charge des patients souffrant de séquelles à long terme d’une infection au SARS-CoV-2 https://www.hug.ch/sites/interhug/files/structures/coronavirus/guidelines-postcovid-29112021.pdf.
19. Nehme M, Braillard O, Chappuis F, Courvoisier DS, Kaiser L, Soccal PM, Reny JL, Assal F, Bondolfi G, Tardin A, Graf C, Zekry D, Stringhini S, Spechbach H, Jacquerioz F, Salamun J, Lador F, Coen M, Agoritsas T, Benzakour L, Favale R, Genevay S, Lauper K, Meyer P, Poku NK, Landis BN, Baggio S, Grira M, Sandoval J, Ehrsam J, Regard S, Genecand C, Kopp G, Guerreiro I, Allali G, Vetter P, Guessous I ; CoviCare Study Team. One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals. J Intern Med. 2022 Jul;292(1):103-115. doi: 10.1111/joim.13482. Epub 2022 Mar 31. PMID: 35555926; PMCID: PMC9115262.
20. Nehme M, Braillard O, Chappuis F, Covicare study team, Guessous I. The chronification of post-COVID condition associated with neurocognitive symptoms, functional impairment and increased healthcare utilization. Scientific Reports [Accepted, in publication].
21. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, Chu HY. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021 Feb 1;4(2):e210830. doi : 10.1001/jamanetworkopen.2021.0830. PMID: 33606031.
22. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021 Jun;594(7862):259-264. doi: 10.1038/s41586-021-03553-9. Epub 2021 Apr 22. PMID: 33887749.
23. World Health Organization. A clinical case defintion of post COVID-19 condition by a Delphi consensus. Last updated October 6, 2021 https://apps.who.int/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf [Access October 10, 2021].
24. Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, Juno JA, Burrell LM, Kent SJ, Dore GJ, Kelleher AD, Matthews GV. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022 Feb;23(2):210-216. doi: 10.1038/s41590-021-01113-x. Epub 2022 Jan 13. PMID: 35027728.
25. Iwasaki A, Putrino D. Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infect Dis 2023. February 14, 2023. https://doi.org/10.1016/S1473-3099(23)00053-1.
26. Chioh FW, Fong SW, Young BE, Wu KX, Siau A, Krishnan S, Chan YH, Carissimo G, Teo LL, Gao F, Tan RS, Zhong L, Koh AS, Tan SY, Tambyah PA, Renia L, Ng LF, Lye DC, Cheung C. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife. 2021 Mar 23;10:e64909. doi : 10.7554/eLife.64909. PMID: 33752798; PMCID: PMC7987341.
27. Couzin-Frankel J. Clues to long COVID. Science. 2022 Jun 17;376(6599):1261-1265. doi: 10.1126/science.add4297. Epub 2022 Jun 16. PMID : 35709281.
28. Barizien N, Le Guen M, Russel S, Touche P, Huang F, Vallée A. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep. 2021 Jul 7 ;11(1):14042. doi : 10.1038/s41598-021-93546-5. PMID: 34234251; PMCID: PMC8263555.
29. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, Lim PB. Autonomic dysfunction in “long COVID”: rationale, physiology and management strategies. Clin Med (Lond). 2021 Jan ;21(1):e63-e67. doi : 10.7861/clinmed.2020-0896. Epub 2020 Nov 26. PMID: 33243837; PMCID: PMC7850225.
30. Bliddal S, Banasik K, Pedersen OB, Nissen J, Cantwell L, Schwinn M, Tulstrup M, Westergaard D, Ullum H, Brunak S, Tommerup N, Feenstra B, Geller F, Ostrowski SR, Grønbæk K, Nielsen CH, Nielsen SD, Feldt-Rasmussen U. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep. 2021 Jun 23;11(1):13153. doi: 10.1038/s41598-021-92045-x. PMID: 34162913; PMCID: PMC8222239.
31. Maglietta G, Diodati F, Puntoni M, Lazzarelli S, Marcomini B, Patrizi L, Caminiti C. Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis. J Clin Med. 2022 Mar 11;11(6):1541.
32. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, Molteni E, Modat M, Jorge Cardoso M, May A, Ganesh S, Davies R, Nguyen LH, Drew DA, Astley CM, Joshi AD, Merino J, Tsereteli N, Fall T, Gomez MF, Duncan EL, Menni C, Williams FMK, Franks PW, Chan AT, Wolf J, Ourselin S, Spector T, Steves CJ. Attributes and predictors of long COVID. Nat Med. 2021 Apr;27(4):626-631. doi: 10.1038/s41591-021-01292-y. Epub 2021 Mar 10. Erratum in: Nat Med. 2021 Jun;27(6):1116. PMID: 33692530; PMCID: PMC7611399.
33. Fernández-de-Las-Peñas C, Torres-Macho J, Velasco-Arribas M, Plaza-Canteli S, Arias-Navalón JA, Hernández-Barrera V, Guijarro C. Preexisting hypertension is associated with a greater number of long-term post-COVID symptoms and poor sleep quality: a case-control study. J Hum Hypertens. 2022 Jun;36(6):582-584. doi: 10.1038/s41371-022-00660-6. Epub 2022 Feb 16. PMID: 35173268; PMCID: PMC8853057.
34. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J, Kornilov SA, Scherler K, Pavlovitch-Bedzyk AJ, Dong S, Lausted C, Lee I, Fallen S, Dai CL, Baloni P, Smith B, Duvvuri VR, Anderson KG, Li J, Yang F, Duncombe CJ, McCulloch DJ, Rostomily C, Troisch P, Zhou J, Mackay S, DeGottardi Q, May DH, Taniguchi R, Gittelman RM, Klinger M, Snyder TM, Roper R, Wojciechowska G, Murray K, Edmark R, Evans S, Jones L, Zhou Y, Rowen L, Liu R, Chour W, Algren HA, Berrington WR, Wallick JA, Cochran RA, Micikas ME; ISB-Swedish COVID-19 Biobanking Unit, Wrin T, Petropoulos CJ, Cole HR, Fischer TD, Wei W, Hoon DSB, Price ND, Subramanian N, Hill JA, Hadlock J, Magis AT, Ribas A, Lanier LL, Boyd SD, Bluestone JA, Chu H, Hood L, Gottardo R, Greenberg PD, Davis MM, Goldman JD, Heath JR. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022 Mar 3;185(5):881-895.e20. doi : 10.1016/j.cell.2022.01.014. Epub 2022 Jan 25. PMID: 35216672; PMCID: PMC8786632.
35. Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, Adamo S, Raeber ME, Bächli E, Rudiger A, Stüssi-Helbling M, Huber LC, Nilsson J, Held U, Puhan MA, Boyman O. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022 Jan 25 ;13(1):446. doi: 10.1038/s41467-021-27797-1. PMID: 35078982; PMCID: PMC8789854.
36. Loosen SH, Jensen BO, Tanislav C, Luedde T, Roderburg C, Kostev K. Obesity and lipid metabolism disorders determine the risk for development of long COVID syndrome: a cross-sectional study from 50,402 COVID-19 patients. Infection. 2022 Oct ;50(5):1165-1170. doi: 10.1007/s15010-022-01784-0. Epub 2022 Mar 30. PMID: 35355237; PMCID: PMC8966865.
37. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, Canas LS, Graham MS, Klaser K, Modat M, Murray B, Kerfoot E, Chen L, Deng J, Österdahl MF, Cheetham NJ, Drew DA, Nguyen LH, Pujol JC, Hu C, Selvachandran S, Polidori L, May A, Wolf J, Chan AT, Hammers A, Duncan EL, Spector TD, Ourselin S, Steves CJ. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2021 Sep 1:S1473-3099(21)00460-6. doi : 10.1016/S1473-3099(21)00460-6. Epub ahead of print. PMID: 34480857; PMCID: PMC8409907.
38. Nehme M, Vetter P, Chappuis F, Kaiser L, Covicare Study Team, Guessous I. Prevalence of post-COVID Condition 12 Weeks after Omicron Infection Compared to Negative Controls and Association with Vaccination Status [in publication].
39. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022 Jun 18;399(10343):2263-2264. doi: 10.1016/S0140-6736(22)00941-2. PMID: 35717982; PMCID: PMC9212672.
40. Espinosa-Gonzalez AB, Master H, Gall N, Halpin S, Rogers N, Greenhalgh T. Orthostatic tachycardia after covid-19. BMJ. 2023 Feb 24;380:e073488. doi : 10.1136/bmj-2022-073488. Erratum in : BMJ. 2023 Mar 21;380:p675. PMID: 36828559.
41. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72. doi: 10.1007/s10286-011-0119-5. PMID: 21431947.
42. Brüne B, Erni S, Huber F, Beise U. Kopfschmerz guideline. 2018 https://www.medix.ch/media/gl_kopfschmerz_2018_19.12.18_mh.pdf.
43. Instructions for patients. BodyMindPower. Inselspital. https://apps.apple.com/ch/app/inselhealth-psychosomatic/id1425902115.
44. Gonthier A, Sommer J. Anxiété en médecine générale : quels types d’autosoins proposer ? [Self-care for anxiety in primary care]. Rev Med Suisse. 2022 May 11 ;18(781):930-933. French. doi : 10.53738/REVMED.2022.18.781.930. PMID : 35543683.
45. Appart, Lange, Sivert, Bihain, Tordeurs. Le trouble de l’adaptation et le DSM-5 : une revue de la littérature, Encéphale, 2017. 43(1):41-46.
46. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabaté Tenas M, Seferovic P, Swedberg K, Tomkowski W; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318. Epub 2015 Aug 29. PMID: 26320112; PMCID: PMC7539677.
47. Schmulson M, Ghoshal UC, Barbara G. Managing the Inevitable Surge of Post-COVID-19 Functional Gastrointestinal Disorders. Am J Gastroenterol. 2021 Jan 1 ;116(1):4-7. doi: 10.14309/ajg.0000000000001062. PMID: 33273261.
48. Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simrén M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2022 Jul;10(6):556-584. doi: 10.1002/ueg2.12259. Epub 2022 Jun 13. PMID: 35695704; PMCID: PMC9278595.
49. Jung A, Andresen V, Layer P. “13. Postinfektiöses Reizdarmsyndrom (RDS)”. Gastroenterologische Infektiologie, edited by Christoph Lübbert and Roger Vogelmann, Berlin, Boston: De Gruyter, 2017, pp. 193-200. https://doi.org/10.1515/9783110464757-015.
50. Dumont R, Richard V, Lorthe E, Loizeau A, Pennacchio F, Zaballa ME, Baysson H, Nehme M, Perrin A, L’Huillier AG, Kaiser L, Barbe RP, Posfay-Barbe KM, Stringhini S ; SEROCoV-KIDS study group; Guessous I. A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents. Nat Commun. 2022 Nov 29;13(1):7086. doi: 10.1038/s41467-022-34616-8. PMID: 36446760; PMCID: PMC9708639.
51. Zimmermann P, Pittet LF, Curtis N. How Common is Long COVID in Children and Adolescents? Pediatr Infect Dis J. 2021 Dec 1;40(12):e482-e487. doi : 10.1097/INF.0000000000003328. PMID: 34870392; PMCID: PMC8575095.
52. Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and clinical presentation of long COVID in children: a systematic review. Eur J Pediatr. 2022 Dec;181(12):3995-4009. doi: 10.1007/s00431-022-04600-x. Epub 2022 Sep 15. PMID: 36107254; PMCID: PMC9476461.
53. Arostegui, Dalia MD; Castro, Kenny MD ; Schwarz, Steven MD ; Vaidy, Katherine MD ; Rabinowitz, Simon MD ; Wallach, Thomas MD Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection, JPGN Reports: February 2022 - Volume 3 - Issue 1 - p e152 doi : 10.1097/PG9.0000000000000152.
54. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001 Aug;39(8):800-12. doi: 10.1097/00005650-200108000-00006. PMID: 11468499.
55. Perrin A, Caflisch M. Nouveau défi : syndrome post-Covid à l’adolescence [A new challenge: post-COVID syndrome in teenagers]. Rev Med Suisse. 2022 Apr 20;18(778):737-740. French. doi: 10.53738/REVMED.2022.18.778.737. PMID: 35451276.
56. Clinicaltrials.gov NCT05497089 trial.Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome https://clinicaltrials.gov/ct2/show/NCT05497089?term=NCT05497089&draw=2&rank=1 [Last accessed January 20, 2023].
57. Clinicaltrials.gov NCT04978259 trial. SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients) https://clinicaltrials.gov/ct2/show/NCT04978259.
58. Forshaw D, Wall EC, Prescott G, et al. STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol. medRxiv 2022;2022.07.21.22277893.
59. Ledford H. Long-COVID treatments: why the world is still waiting. Nature. 2022 Aug;608(7922):258-260. doi: 10.1038/d41586-022-02140-w. PMID: 35945375.
60. Davis, H.E., McCorkell, L., Vogel, J.M. et al. Long COVID : major findings, mechanisms and recommendations. Nat Rev Microbiol (2023). https://doi.org/10.1038/s41579-022-00846-2.
61. World Health Organization Rehabilitation: key for health in the 21st century. Rehabilitation 2030: a call for action. 2017. Available at: http://www.who.int/disabilities/care/rehab-2030/en/.
62. Law M, Baptiste S, McColl M, Opzoomer A, Polatajko H, Pollock N. The Canadian occupational performance measure: an outcome measure for occupational therapy. Can J Occup Ther. 1990 Apr;57(2):82-7. doi: 10.1177/000841749005700207. PMID: 10104738.
63. Baron K, Kielhofner G, Iyenger A, Goldhammer V, Wolenski J. The Occupational Self Assessment (version 2.2) Model of Human Occupation Clearinghouse, Department of Occupational Therapy, College of Applied Health Sciences, University of Illinois at Chicago; Chicago : 2006.
64. Hersche R, Weise A. Occupational Therapy-Based Energy Management Education in People with Post-COVID-19 Condition-Related Fatigue: Results from a Focus Group Discussion. Occupational Therapy International, vol. 2022, Article ID 4590154, 9 pages, 2022. https://doi.org/10.1155/2022/4590154.
65. Postigo-Martin P, Cantarero-Villanueva I, Lista-Paz A, Castro-Martín E, Arroyo-Morales M, Seco-Calvo J : A COVID-19 Rehabilitation Prospective Surveillance Model for Use by Physiotherapists. JCM 2021;10(8):1691.
66. Ries A. Minimally Clinically Important Difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale, COPD: Journal of Chronic Obstructive Pulmonary Disease, 2:1, 105-110, DOI: 10.1081/COPD-200050655.
67. Fu Q, Levine BD : Exercise in the postural orthostatic tachycardia syndrome. Auton Neurosci 2015;188 86-89.
68. Nehme M, Chappuis F, Kaiser L, Assal F, Guessous I. The Prevalence, Severity, and Impact of Post-COVID Persistent Fatigue, Post-Exertional Malaise, and Chronic Fatigue Syndrome. J Gen Intern Med. 2022 Nov 10:1–5. doi: 10.1007/s11606-022-07882-x. Epub ahead of print. PMID: 36357723; PMCID: PMC9648889.
69. Bach K. New data shows long Covid is keeping as many as 4 million people out of work. Brookings Institute. Aug 24, 2022.
70. Sheehan, DV . The Anxiety Disease. New York: Charles Scribner and Sons, 1983.
71. Bell DS. The Doctor’s Guide to Chronic Fatigue Syndrome: Understanding, Treating and Living with CFIDS. Boston : Da Capo Lifelong Books; 1995.
72. Supporting occupational health and wellbeing professionals. COVID-19 return to work guide. https://www.som.org.uk/COVID-19_return_to_work_guide_for_recovering_workers.pdf.
73. Supporting occupational health and wellbeing professionals. COVID-19 return to work guide for managers. https://www.som.org.uk/COVID-19_return_to_work_guide_for_managers.pdf?fbclid=IwAR3EfGr81n53BrLji0ZmLn1AAOPqGFGjXZDR9NdL_p2vaZyebvJQPZMAHNI.
74. Groupe de travail post-COVID-19. Médecine d’assurance. Recommandation pour le bilan de médecine d’assurance d’une affection post-COVID-19 en Suisse. https://www.swiss-insurance-medicine.ch/storage/app/media/Downloads/Dokumente/covid-19/220317_Post-Covid-19-Erkrankung_Empfehlung_FR.pdf.
75. EPOCA - Questionnaire for the evaluation of post-COVID condition https://www.swiss-insurance-medicine.ch/storage/app/media/Downloads/Dokumente/covid-19/EPOCA_Erfassungsbogen_Version_01.2_17.03.2022.pdf.
